Vaccine-Associated Sarcoma in Cats: Welfare and Management
Vaccine-associated sarcoma (FISS) is an aggressive tumor arising at injection sites in cats, requiring aggressive treatment and creating significant welfare challenges.
Key Facts
- Occurs at a rate of approximately 1-3 per 10,000 vaccine doses administered
- Caused by local inflammation triggering malignant transformation in susceptible cats
- Highly aggressive with local invasion and high metastatic potential
- Wide surgical excision with at least 3 cm margins is essential for best outcomes
- Chemotherapy and radiation therapy used adjunctively improve survival times
Welfare Considerations
Vaccine-associated sarcoma creates profound welfare challenges through its aggressive growth, high recurrence rates, and the extensive surgery required for best outcomes. Affected cats require intensive multimodal treatment, including major surgery, radiation, and chemotherapy. The welfare burden of treatment is significant, but untreated tumors grow rapidly and are invariably fatal. Informed consent discussions must honestly address both the welfare costs of treatment and the poor prognosis even with aggressive management. The preventable elementāusing low-antigen vaccines, rotating sites, and giving vaccines only when neededāreduces but does not eliminate risk.
What You Can Do
- Discuss vaccine protocols with your vet to minimize injection site reactions
- Monitor injection sites closely for 1-3 months after vaccination
- Seek immediate veterinary assessment for any lump persisting beyond 4 weeks
- Request referral to a specialist oncologist if FISS is suspected
- Make treatment decisions based on honest welfare prognosis discussions with your vet